DE69808258D1 - Molekül-agonisten für den insulinähnlichen wachstumfaktor - Google Patents

Molekül-agonisten für den insulinähnlichen wachstumfaktor

Info

Publication number
DE69808258D1
DE69808258D1 DE69808258T DE69808258T DE69808258D1 DE 69808258 D1 DE69808258 D1 DE 69808258D1 DE 69808258 T DE69808258 T DE 69808258T DE 69808258 T DE69808258 T DE 69808258T DE 69808258 D1 DE69808258 D1 DE 69808258D1
Authority
DE
Germany
Prior art keywords
insulin
growth factor
molecule agonists
igf
growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69808258T
Other languages
English (en)
Other versions
DE69808258T2 (de
Inventor
G Clark
B Lowman
C Robinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DE69808258D1 publication Critical patent/DE69808258D1/de
Publication of DE69808258T2 publication Critical patent/DE69808258T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4743—Insulin-like growth factor binding protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides
DE69808258T 1997-04-04 1998-03-31 Molekül-agonisten für den insulinähnlichen wachstumfaktor Expired - Lifetime DE69808258T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/825,852 US6121416A (en) 1997-04-04 1997-04-04 Insulin-like growth factor agonist molecules
PCT/US1998/006514 WO1998045427A2 (en) 1997-04-04 1998-03-31 Insulin-like growth factor agonist peptides

Publications (2)

Publication Number Publication Date
DE69808258D1 true DE69808258D1 (de) 2002-10-31
DE69808258T2 DE69808258T2 (de) 2003-09-18

Family

ID=25245064

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69808258T Expired - Lifetime DE69808258T2 (de) 1997-04-04 1998-03-31 Molekül-agonisten für den insulinähnlichen wachstumfaktor

Country Status (13)

Country Link
US (16) US6121416A (de)
EP (2) EP1251137A3 (de)
JP (1) JP4562814B2 (de)
AT (1) ATE224951T1 (de)
AU (1) AU732989B2 (de)
CA (1) CA2286264A1 (de)
DE (1) DE69808258T2 (de)
DK (1) DK0972020T3 (de)
ES (1) ES2183344T3 (de)
HK (1) HK1047755A1 (de)
IL (1) IL131925A0 (de)
PT (1) PT972020E (de)
WO (1) WO1998045427A2 (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
ES2329220T3 (es) 1999-01-06 2009-11-24 Genentech, Inc. Variantes mutantes del factor de crecimiento similar a insulina (igf) i.
WO2000040613A1 (en) 1999-01-06 2000-07-13 Genentech, Inc. Insulin-like growth factor (igf) i mutant variants
US20030224017A1 (en) * 2002-03-06 2003-12-04 Samal Siba K. Recombinant Newcastle disease viruses useful as vaccines or vaccine vectors
CA2389575A1 (en) * 1999-10-29 2001-05-10 Oregon Health Sciences University Modulation of neuroendocrine differentiation by protein 25.1
EP1265630B1 (de) 2000-03-24 2006-06-07 Genentech, Inc. Verwendung von insulin zur behandlung von knorpelkrankheiten
EP1282437B1 (de) 2000-05-16 2008-03-19 Genentech, Inc. Behandlung von knorpelerkrankungen
FR2810675B1 (fr) * 2000-06-22 2002-09-27 Pf Medicament Construction modifiee en aval du codon d'initiation pour la surexpression de proteines recombinantes
AU3956002A (en) * 2000-11-28 2002-06-11 Childrens Medical Center Determination of risk and treatment of complications of prematurity
US7611711B2 (en) * 2001-01-17 2009-11-03 Vegenics Limited VEGFR-3 inhibitor materials and methods
DE60233359D1 (de) * 2001-02-09 2009-09-24 Genentech Inc Verfahren zur Identifizierung von indirekten IGF-1-Agonisten
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
US6790672B2 (en) * 2001-02-19 2004-09-14 Board Of Regents The University Of Texas System Encoded molecular sieve particle-based sensors
CA2702192A1 (en) 2001-03-14 2002-09-19 Genentech, Inc. Igf antagonist peptides
US6841386B2 (en) 2001-04-10 2005-01-11 Viacell, Inc. Modulation of primary stem cell differentiation using an insulin-like growth factor binding protein
US7232798B2 (en) 2001-11-13 2007-06-19 Tran Loi H Neuroprotection and neuroegenisis by administering cyclic prolyl glycine
US20100247483A1 (en) * 2001-11-13 2010-09-30 Tran Loi H Therapeutic agent composition and method of use
WO2003041655A2 (en) * 2001-11-13 2003-05-22 Loi Tran Therapeutic agent composition and method of use
JP4563171B2 (ja) 2002-05-24 2010-10-13 シェーリング コーポレイション 中和ヒト抗ｉｇｆｒ抗体
AU2003273615B2 (en) * 2002-06-11 2010-07-29 Brigham And Women's Hospital Neuroprotective synergy of erythropoietin and insulin-like growth factor
US7118877B2 (en) * 2002-07-08 2006-10-10 Wyeth Caspase 9 activation and uses therefor
WO2004022083A1 (en) * 2002-09-04 2004-03-18 Dsm Ip Assets B.V. A nutritional and therapeutic composition of an insulin sensitizer and a peptide fraction
WO2004023647A1 (en) * 2002-09-06 2004-03-18 Telefonaktiebolaget Lm Ericsson Composite power amplifier
US20040121407A1 (en) * 2002-09-06 2004-06-24 Elixir Pharmaceuticals, Inc. Regulation of the growth hormone/IGF-1 axis
RU2005111253A (ru) * 2002-09-18 2005-11-20 Сантр Оспиталье Де Л` Юниверсите Де Монреаль (Схюм) (Ca) Аналоги ghrh
CA2504607A1 (en) * 2002-11-14 2004-05-27 Wyeth Methods and compositions for treating neurological disorders
US7273788B2 (en) * 2003-05-21 2007-09-25 Micron Technology, Inc. Ultra-thin semiconductors bonded on glass substrates
WO2005001486A1 (en) 2003-06-06 2005-01-06 Genentech, Inc. Modulating the interaction between hgf beta chain and c-met
US7920906B2 (en) 2005-03-10 2011-04-05 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
ATE536186T1 (de) 2003-09-12 2011-12-15 Tercica Inc Verfahren zur behandlung von igf-1 (insulin-like growth factor 1)-mangel
EP1670822A2 (de) * 2003-10-03 2006-06-21 Genentech, Inc. Igf-bindende proteine
CN1938428A (zh) 2003-11-12 2007-03-28 先灵公司 多基因表达的质粒系统
US9247900B2 (en) 2004-07-13 2016-02-02 Dexcom, Inc. Analyte sensor
TW200526684A (en) 2003-11-21 2005-08-16 Schering Corp Anti-IGFR1 antibody therapeutic combinations
CA2548282A1 (en) 2003-12-11 2005-06-30 Genentech, Inc. Methods and compositions for inhibiting c-met dimerization and activation
AU2005224942B2 (en) * 2004-03-19 2011-08-11 Merck Patent Gmbh Modified bouganin proteins, cytotoxins and methods and uses thereof
US7946984B2 (en) 2004-07-13 2011-05-24 Dexcom, Inc. Transcutaneous analyte sensor
WO2006127694A2 (en) 2004-07-13 2006-11-30 Dexcom, Inc. Analyte sensor
DE602005025685D1 (de) 2004-12-03 2011-02-10 Schering Corp Biologische marker zur vorauswahl von patienten für die anti-igf1r-therapie
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
CA2604393A1 (en) * 2005-04-15 2006-10-26 Schering Corporation Methods and compositions for treating or preventing cancer
AU2006259536A1 (en) * 2005-06-15 2006-12-28 Schering Corporation Anti-IGF1R antibody formulations
EP2343551B1 (de) 2006-04-10 2014-05-28 Genentech, Inc. Dishevelled PDZ-Modulatoren
US8518877B2 (en) * 2007-04-18 2013-08-27 Premacure Ab Method and product for treatment and/or prevention of complications of prematurity
JP2010536880A (ja) 2007-08-22 2010-12-02 ギリード・コロラド・インコーポレーテッド 糖尿病の合併症のための療法
WO2009105709A1 (en) 2008-02-21 2009-08-27 Dexcom, Inc. Systems and methods for processing, transmitting and displaying sensor data
US8682408B2 (en) 2008-03-28 2014-03-25 Dexcom, Inc. Polymer membranes for continuous analyte sensors
US8583204B2 (en) 2008-03-28 2013-11-12 Dexcom, Inc. Polymer membranes for continuous analyte sensors
US11730407B2 (en) 2008-03-28 2023-08-22 Dexcom, Inc. Polymer membranes for continuous analyte sensors
EP2571992B1 (de) 2010-05-21 2018-04-25 Merrimack Pharmaceuticals, Inc. Bispezifische fusionsproteine
CA2812785A1 (en) 2010-10-20 2012-04-26 Genentech, Inc. Methods and compositions for modulating the wnt pathway
JP6190813B2 (ja) 2011-10-14 2017-08-30 ジェネンテック， インコーポレイテッド チモーゲン活性化因子
WO2013056054A2 (en) 2011-10-14 2013-04-18 Genentech, Inc Peptide inhibitors of bace1
CN108367048B (zh) 2015-10-02 2022-08-12 银溪制药股份有限公司 用于组织修复的双特异性治疗性蛋白质
EP3681602A1 (de) 2017-09-11 2020-07-22 Shire Human Genetic Therapies, Inc. Verfahren und zusammensetzungen zur behandlung chronischer lungenerkrankungen
JP2021524864A (ja) 2018-05-15 2021-09-16 ロイド ハン ロイ トランＬｌｏｙｄ Ｈｕｎｇ Ｌｏｉ Ｔｒａｎ 軽度の認知障害、抑うつ、および精神障害の治療のための治療薬組成物およびその使用方法
US20210008172A1 (en) 2019-07-11 2021-01-14 Opko Biologics Ltd. Long-acting igf-1 or igf-1 variants and methods of producing same
GB201913196D0 (en) 2019-09-12 2019-10-30 Univ Newcastle Culture method
US20230381285A1 (en) 2020-10-19 2023-11-30 Oak Hill Bio Ltd Compositions suitable for use in neonates
DE102021122096A1 (de) 2021-08-26 2023-03-02 Forschungsinstitut für Nutztierbiologie IGF-1, IGFBP-2 und Insulin umfassende Zusammensetzungen und ihre Verwendung
WO2023139115A1 (en) 2022-01-19 2023-07-27 Oak Hill Bio Limited Compositions and methods for reducing oxidation of igf‐1/igfbp
CN117347626B (zh) * 2023-12-06 2024-03-12 安徽惠邦生物工程有限公司 人胰岛素样生长因子结合蛋白-1化学发光免疫分析试剂盒及其制备方法

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4411890A (en) * 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US3721252A (en) * 1971-04-01 1973-03-20 Catheter And Instr Corp Spring guide washer
US4511503A (en) * 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
IL71991A (en) * 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
PH23185A (en) 1983-06-13 1989-05-29 Scheindel Ass Inc Pressure operated dispensing container
WO1985000831A1 (en) * 1983-08-10 1985-02-28 Amgen Microbial expression of insulin-like growth factor
DE3463991D1 (en) 1983-08-15 1987-07-02 Amp Inc An improved compliant section for circuit board contact elements
WO1987001038A1 (en) * 1985-08-22 1987-02-26 Commonwealth Scientific And Industrial Research Or Peptide analogues of mammalian insulin-like growth factor-1
SE8505922D0 (sv) * 1985-12-13 1985-12-13 Kabigen Ab Construction of an igg binding protein to facilitate downstream processing using protein engineering
ATE90690T1 (de) * 1987-04-06 1993-07-15 Celtrix Pharma Menschliche somatomedin-traeger-proteinuntereinheiten und verfahren zu ihrer herstellung.
CA1314507C (en) * 1987-04-23 1993-03-16 Edith Yee-Tak Wong Secretion of insulin-like growth factor-i in e. coli
SE8703625D0 (sv) * 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
US4876242A (en) * 1987-09-21 1989-10-24 Merck & Co., Inc. Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast
US5470828A (en) * 1987-12-24 1995-11-28 Gropep Pty. Ltd. Peptide analogs of insulin-like growth factor II
WO1989005822A1 (en) * 1987-12-24 1989-06-29 Gropep Pty. Ltd. Peptide analogues of insulin-like growth factor 1 (igf-1) or factor 2 (igf-2)
US4988675A (en) * 1988-02-05 1991-01-29 Ciba-Geigy Corporation Method for preventing secondary effects
EP0327503B1 (de) * 1988-02-05 1993-03-10 Ciba-Geigy Ag Verwendung von IGF I zur Herstellung eines Präparates für die Behandlung von Nierenkrankheiten
DK131988A (da) * 1988-03-11 1989-09-12 Erasmus University Igf-bindingsprotein, dna-struktur, der koder for igf-bindingsproteinet og vektor indeholdende denne dna-struktur
US5258287A (en) * 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
WO1989009792A1 (en) * 1988-04-12 1989-10-19 Synergen, Inc. Method for potentiating and inhibiting insulin-like growth factor activity
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5534617A (en) * 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
GB8826451D0 (en) * 1988-11-11 1988-12-14 Sandoz Ltd Improvements in/relating to organic compounds
IL92816A0 (en) * 1988-12-22 1990-09-17 Biogrowth Inc Recombinant dna molecules,hosts,processes and human somatomedin carrier protein-like polypeptides
EP0379338A3 (de) * 1989-01-17 1991-07-24 Merck & Co. Inc. Menschlicher insulinähnlicher Wachstumsfaktor und seine Herstellung in Hefe
US5652214A (en) * 1989-06-05 1997-07-29 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
GB8920381D0 (en) * 1989-09-08 1989-10-25 Greater Glasgow Health Board Treatment of insulin-resistant diabetes
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
US5374620A (en) * 1990-06-07 1994-12-20 Genentech, Inc. Growth-promoting composition and its use
US5210017A (en) * 1990-11-19 1993-05-11 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
US5593844A (en) * 1990-11-19 1997-01-14 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
SE9100099D0 (sv) * 1991-01-11 1991-01-11 Kabi Pharmacia Ab Use of growth factor
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
CA2105300C (en) * 1991-03-01 2008-12-23 Robert C. Ladner Process for the development of binding mini-proteins
US5206235A (en) * 1991-03-20 1993-04-27 Merck & Co., Inc. Benzo-fused lactams that promote the release of growth hormone
US5202119A (en) * 1991-06-28 1993-04-13 Genentech, Inc. Method of stimulating immune response
DE69218948T2 (de) * 1991-08-01 1997-07-31 Genentech Inc IGF-I zur Verbesserung der neuronale Lage
US6310040B1 (en) * 1991-11-08 2001-10-30 Cephalon, Inc. Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs
SE9201573D0 (sv) * 1992-05-19 1992-05-19 Kabi Pharmacia Ab Use of igf-1
WO1993025219A1 (en) * 1992-06-12 1993-12-23 Cephalon, Inc. Prevention and treatment of peripheral neuropathy
GB9217696D0 (en) * 1992-08-20 1992-09-30 Agricultural & Food Res Use of specific binding molecules
US5273961A (en) * 1992-09-22 1993-12-28 Genentech, Inc. Method of prophylaxis of acute renal failure
WO1994016722A1 (en) * 1993-01-25 1994-08-04 The Beth Israel Hospital Association Method for modifying, diagnosing, and screening for igf-i sensitive cell barrier properties
CA2154078A1 (en) * 1993-01-29 1994-08-04 George N. Cox Wound healing composition
US5457109A (en) * 1993-09-15 1995-10-10 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
DE69427650T2 (de) * 1993-12-23 2001-11-22 Novo Nordisk As Verbindungen mit wachstumshormon-freisetzenden eigenschaften
JP3181918B2 (ja) * 1993-12-23 2001-07-03 ノボ ノルディスク アクティーゼルスカブ 成長ホルモン放出特性を持つ化合物
SE9402370D0 (sv) * 1994-07-04 1994-07-04 Pharmacia Ab Use of IGF-I
US5798337A (en) * 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
SE9501472D0 (sv) * 1995-04-21 1995-04-21 Pharmacia Ab Truncated IGF-I
US5622932A (en) * 1995-05-05 1997-04-22 Eli Lilly And Company IGF-1 superagonists
DK0828758T3 (da) * 1995-05-26 2002-01-07 Theratechnologies Inc Kimæriske fedtlegeme-pro-GRF-analoger med forøget biologisk potensering
AU6046696A (en) * 1995-06-07 1996-12-30 Glaxo Group Limited Peptides and compounds that bind to a receptor
ZA964814B (en) * 1995-06-07 1998-02-09 Glaxo Group Ltd Peptides and compounds that bind to a receptor.
CZ391097A3 (cs) * 1995-06-07 1998-07-15 Ortho Pharmaceutical Corporation Látky a peptidy vážící se na erythropoietinový receptor
US5958872A (en) * 1996-04-01 1999-09-28 Apoptosis Technology, Inc. Active survival domains of IGF-IR and methods of use
JPH11508608A (ja) * 1996-04-17 1999-07-27 ニューロクライン バイオサイエンシーズ，インコーポレイテッド インスリン様成長因子結合タンパク質のリガンドインヒビターおよびそれらの使用方法
US6402715B2 (en) 1996-04-25 2002-06-11 Karl Storz Gmbh & Co. Kg Surgical instrument system
AU7891098A (en) 1996-12-27 1998-07-31 Daiichi Pharmaceutical Co., Ltd. Method for elevating the concentration of free insulin-like growth factor
US6420518B1 (en) * 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
WO2000023469A2 (en) 1998-10-16 2000-04-27 Musc Foundation For Research Development Fragments of insulin-like growth factor binding protein and insulin-like growth factor, and uses thereof

Also Published As

Publication number Publication date
CA2286264A1 (en) 1998-10-15
US6608031B1 (en) 2003-08-19
DK0972020T3 (da) 2003-02-03
US6121416A (en) 2000-09-19
EP1251137A3 (de) 2003-04-16
US6645775B1 (en) 2003-11-11
US6680298B1 (en) 2004-01-20
US6251865B1 (en) 2001-06-26
DE69808258T2 (de) 2003-09-18
US6949349B1 (en) 2005-09-27
AU6947098A (en) 1998-10-30
JP4562814B2 (ja) 2010-10-13
HK1047755A1 (zh) 2003-03-07
US6689751B1 (en) 2004-02-10
WO1998045427A2 (en) 1998-10-15
WO1998045427A3 (en) 1999-01-07
US6693078B1 (en) 2004-02-17
EP1251137A2 (de) 2002-10-23
US6716586B1 (en) 2004-04-06
US6632794B1 (en) 2003-10-14
US6713451B1 (en) 2004-03-30
US6677305B1 (en) 2004-01-13
AU732989B2 (en) 2001-05-03
IL131925A0 (en) 2001-03-19
EP0972020A1 (de) 2000-01-19
ATE224951T1 (de) 2002-10-15
EP0972020B1 (de) 2002-09-25
JP2002510194A (ja) 2002-04-02
PT972020E (pt) 2003-02-28
US6693079B1 (en) 2004-02-17
US6683053B1 (en) 2004-01-27
US6620789B1 (en) 2003-09-16
ES2183344T3 (es) 2003-03-16
US6635619B1 (en) 2003-10-21

Similar Documents

Publication Publication Date Title
ATE224951T1 (de) Molekül-agonisten für den insulinähnlichen wachstumfaktor
CANALIS Effect of growth factors on bone cell replication and differentiation
ATE211171T1 (de) Weitgehend reine rezeptorartige, tgf-beta-1- bindende moleküle und deren verwendungen
DE69033109T2 (de) Rezeptoren für fibroblasten-wachstumsfaktoren
EA200000652A1 (ru) Кристаллы глюкагоноподобного пептида 1
BR9714434A (pt) Formulações de interferon liquidas estáveis
EA200000298A1 (ru) Агонисты простагландинов и их применение для лечения заболеваний костей
CY1112101T1 (el) Νευροτροφικοι παραγοντες
ES2139012T3 (es) Peptidos de la proteina p53 humana destinados para ser utilizados en composiciones que inducen una reaccion en los linfocitos t humanos, y linfocitos t citotoxicos especificos de la proteina p53 humana.
DE60038922D1 (de) Zusammensetzungen für den wiederaufbau von knochengewebe
BRPI0413521A (pt) seqüências de aminoácidos que facilitam a penetração de uma substáncia de interesse nas células e/ou no núcleos celulares
DK1282437T3 (da) Behandling af brusklidelser
BR9508467A (pt) Composição de matéria peptídeo de ligação de receptor de somatostatina composição farmacéutica e processo para realizar uma cirurgia guiada por radiosótopos ou um procedimento de radiodiagnóstico ou radioterapéutico e para aliviar uma doença relacionada com somatostetina em um animal
BR0013638A (pt) Novas moléculas semelhantes a interferon beta
ATE400294T1 (de) Neue antimikrobielle polypeptide und verfahren für ihre verwendung.
PT877803E (pt) Receptor da proteina ob e composicoes e metodos afins
DK0486572T3 (da) Forbedringer i granulocyt-makrofag-kolonistimulerende faktorreceptor og derivater deraf
DE69426076D1 (de) Gereinigte flt3 liganden von saeugentieren, agonisten und antagonisten davon
FI972170A (fi) Peptidejä, jotka kykenevät sitoutumaan GAP-proteiinin SH3-domeeniin, näitä peptidejä koodittavia nukleotidisekvenssejä, niiden valmistus ja käyttö
EE05182B1 (et) Asendatud homopiperidlbensimidasooli analoog, meetod selle valmistamiseks ning seda sisaldav farmatseutiline kompositsioon
WO2000073326A3 (en) Redox-stable, non-phosphorylated cyclic peptide inhibitors of sh2 domain binding to target protein, conjugates thereof, compositions and methods of synthesis and use
BR9804921A (pt) Peptìdeo natriurético atrial (anp) como um aditivo para soluções de diálise peritoneal.
ATE441642T1 (de) Hydantoin derivate mit affinität für somatostatin rezeptoren
DK1073623T3 (da) Substituerede aminosyrer som erythropoietin-mimetika
DE10080849D2 (de) Fragmente des Virus Proteins 2 oder 3 des Polymavirus als Fähren für Wirkstoffe

Legal Events

Date Code Title Description
8364 No opposition during term of opposition